Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AbbVie

AbbVie Stock Dives As Cosmetic Sales Mar Its Third-Quarter Beat And Guidance Boost

AbbVie posted a nearly perfect third-quarter beat Friday, but AbbVie stock skidded on light aesthetics sales and as Humira sales fell.

Investors Business Daily

Drugmaker AbbVie Stock Sees Improved Relative Price Strength

A Relative Strength Rating upgrade for AbbVie shows improving technical performance. Will it continue?

Investors Business Daily

AbbVie Stock Moves Higher With Rising Relative Strength

A Relative Strength Rating upgrade for AbbVie shows improving technical performance. Will it continue?

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

AbbVie Stock Shows Rising Relative Strength Rating

AbbVie shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Former IBD 50 Stock Revance Implodes As Its 'Prestige' Plan Goes Up In Smoke

Revance is reversing course to stay competitive with AbbVie's aesthetics drug, Botox — and RVNC stock crashed Tuesday in response.

Investors Business Daily

Top 3 Pharma Stocks to Boost Your Portfolio

As the global population ages and faces the increasing toll of chronic diseases, the pharmaceutical industry is expected to step up to meet people’s healthcare needs. Against this backdrop, pharma companies like Novo Nordisk (NVO), AbbVie (ABBV), and Novartis (NVS) could boost your portfolio. Read on….

StockNews.com

Building Wealth with Spinoffs: How Adding These Gems Can Transform Your Portfolio

Spinoffs are value creating investment opportunities. You should be looking at them

Barchart

Read news from The Economist, FT, and more,
with one subscription

The Unexpected Bad News For Novo's Ozempic In Biden's Drug Negotiations List

Drugs from AbbVie, Bristol and Merck took slots on the list of drugs subject to price cuts. But the pharmaceutical stocks were unmoved.

Investors Business Daily

CVS is launching a genius way to cut costs for its customers

The drugstore is exploring new territory in a growing industry.

The Street

Big Pharma’s playbook for expensive meds

Here are just a few of the many examples of drug pricing practices that have driven consumers to demand change

Salon

How Revance Is Taking A Page Out Of AbbVie's Botox Playbook

Revance's frown-line injection, Daxxify, gained U.S. approval on Monday to treat an involuntary movement disorder, and RVNC stock rose.

Investors Business Daily

Are Pfizer (PFE) and AbbVie (ABBV) Good Value Buys for August?

The pharma industry is poised to witness long-term growth with the introduction of generic medicines and growing demand for personalized and targeted treatments. Hence, fundamentally strong pharma stock AbbVie (ABBV) might be worth buying. However, it might not be the right time to invest in Pfizer (PFE). Keep reading.

StockNews.com

AbbVie’s Underperformance, Deere’s Catch-Up Potential, And Pioneer’s Earnings Awaited

AbbVie's underperformance, Jim Lebenthal sees Deere as a catch-up trade, and analysts await Pioneer's earnings report.

Zenger

3 High-Paying Unusually Active Put Options to Sell for Extra Cash This Weekend

It’s the last day of the trading week, so investors are looking for extra spending money for the weekend ahead. Here are three unusually active put options to sell: high-paying and worthwhile long-term holds.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

AbbVie Results Fall But The Drop Isn't As Severe As Expected; Shares Climb

Drug maker AbbVie reported second-quarter profit and sales that fell from a year earlier but topped expectations. AbbVie stock rose.

Tribune News Service

Humira, the world’s top-selling drug, faces an upcoming test from low cost alternatives

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor.

The Independent UK

Cheaper competition for Humira is hitting the market, but savings will depend on your insurance

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July

Barchart

3 Dependable Dividend Stocks to Consider in the Second Half Of 2023

These 3 dividend stocks have uninterruptedly paid and raised their dividends for years. Further, these stocks have outperformed the broader markets, and Wall Street analysts have a favorable outlook on them.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree

Big Pharma has a problem, and buying up biotech companies helps solve it. But the FTC has its own ideas about industry mergers. Here's where things stand.

Kiplinger

Best Retirement Stocks for Income Investors in the Golden Years

The best retirement stocks ideally have attractive dividends that can be sustained. This can lead to steady income and long-term value for retirees.

Investors Business Daily

Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review

The stock market rally went to "under pressure" amid big earnings moves and revived banking fears, but the major indexes ultimately closed tightly again.

Investors Business Daily

Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?

Industry analysts warn that a groundbreaking change in how Medicare buys drugs threatens industry growth, profits — and maybe patient care.

Investors Business Daily

AbbVie's Humira Downfall Is Swift As Biosimilars Hammer Away At Sales

AbbVie stock crumbled Thursday after the first biosimilar to launch in the U.S. hammered away at Humira's legendary sales.

Investors Business Daily

Dow Jones Futures Rise: Meta Soars, Drug Giants Climb, Specialty Chip Plays Dive

Futures: Meta Platforms boomed on earnings, but megacap techs can't hide broad market rally weakness. First Republic dived again.

The Street

AbbVie Stock Holds Support and Gives Traders a Buying Opportunity

AbbVie stock has been trading well and investors are looking for a breakout.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations